InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,859.85
(
0.77%
)
US TECH 100
19,900.00
(
0.00%
)
Dow Jones
43,065.22
(
0.47%
)
Brent Oil
74.45
(
-0.62%
)
Bitcoin
65,670.92
(
-0.58%
)
Post# of 366142
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Nolerman

Send PM Follow Ignore
Followers 100
Posts 7904
Boards Moderated 1
Alias Born 11/04/2012

Nolerman

Re: None

Tuesday, 02/25/2014 8:16:08 AM

Tuesday, February 25, 2014 8:16:08 AM

Post# of 366142
ITMN
InterMune's Pirfenidone meets Phase III trial goals
Tuesday, February 25, 7:34 AM ET | ITMN
InterMune's (ITMN) Pirfenidone drug met the primary goal of a Phase III trial by significantly reducing the progression of idiopathic pulmonary fibrosis (IPF) or mortality.
"IPF is an irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis (scarring) in the lungs, which hinders the ability of lungs to absorb oxygen," InterMune explains. IPF's five-year survival rate is 20-40%.
Pirfenidone also met secondary endpoints with improvements in six-minute walk tests and progression-free survival.
InterMune now plans to resubmit an application for FDA authorization of Pirfenidone.
Trading in the firm's shares has been halted. (PR)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up